- Home
- ACAD vs MCY Comparison
ACAD vs MCY Comparison
Compare ACAD & MCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- MCY
- Stock Information
- Founded
- ACAD 1993
- MCY 1961
- Country
- ACAD United States
- MCY United States
- Employees
- ACAD N/A
- MCY N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- MCY Property-Casualty Insurers
- Sector
- ACAD Health Care
- MCY Finance
- Exchange
- ACAD Nasdaq
- MCY Nasdaq
- Market Cap
- ACAD 3.8B
- MCY 3.1B
- IPO Year
- ACAD 2004
- MCY N/A
- Fundamental
- Price
- ACAD $20.98
- MCY $66.10
- Analyst Decision
- ACAD Buy
- MCY Strong Buy
- Analyst Count
- ACAD 18
- MCY 1
- Target Price
- ACAD $27.71
- MCY $80.00
- AVG Volume (30 Days)
- ACAD 2.0M
- MCY 265.6K
- Earning Date
- ACAD 08-05-2025
- MCY 07-29-2025
- Dividend Yield
- ACAD N/A
- MCY 1.91%
- EPS Growth
- ACAD N/A
- MCY 32.82
- EPS
- ACAD 1.37
- MCY 5.16
- Revenue
- ACAD $996,283,000.00
- MCY $5,595,427,000.00
- Revenue This Year
- ACAD $13.39
- MCY $7.13
- Revenue Next Year
- ACAD $10.59
- MCY $7.60
- P/E Ratio
- ACAD $15.33
- MCY $12.87
- Revenue Growth
- ACAD 22.42
- MCY 16.64
- 52 Week Low
- ACAD $13.40
- MCY $44.19
- 52 Week High
- ACAD $25.23
- MCY $80.72
- Technical
- Relative Strength Index (RSI)
- ACAD 45.70
- MCY 55.67
- Support Level
- ACAD $20.75
- MCY $64.21
- Resistance Level
- ACAD $23.09
- MCY $67.41
- Average True Range (ATR)
- ACAD 0.78
- MCY 1.49
- MACD
- ACAD -0.20
- MCY -0.17
- Stochastic Oscillator
- ACAD 9.83
- MCY 60.08
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About MCY Mercury General Corporation
Mercury General Corp is an insurance holding company. It is engaged in writing personal automobile insurance and provides related property and casualty insurance products. The Company offers the following types of automobile coverage: collision, property damage, bodily injury ("BI"), comprehensive, personal injury protection ("PIP"), underinsured and uninsured motorist, and other hazards. The Company offers the following types of homeowners coverage: dwelling, liability, personal property, and other coverages.